title: Is cyclosporine administration in twice daily dose advantageous?
authors.affiliation: Institute of Nephrology, University of Brescia, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Savoldi
authors.forename: S
authors.initials: S
authors.lastname: Sandrini
authors.forename: F
authors.initials: F
authors.lastname: Scolari
authors.forename: G
authors.initials: G
authors.lastname: Brunori
authors.forename: E
authors.initials: E
authors.lastname: Prati
authors.forename: C
authors.initials: C
authors.lastname: Camerini
authors.forename: P
authors.initials: P
authors.lastname: Scaini
authors.forename: L
authors.initials: L
authors.lastname: Cristinelli
authors.forename: R
authors.initials: R
authors.lastname: Maiorca
mesh_terms: D003524:Cyclosporins / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D016030:Kidney Transplantation / Q000473:pathology / Q000502:physiology*; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008775:Methylprednisolone / Q000627:therapeutic use; D011863:Radioimmunoassay
chemical_list: D003524:Cyclosporins; D008775:Methylprednisolone